Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | CRHBP | P24387 | 2/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21424970 | 0.78 | ALDH1A1 (0.47) | KMT2AMEN1MAPTEGFRKCNH2 | |
| SCHEMBL13390779 | 0.78 | ALDH1A1 (0.52) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL16370809 | 0.74 | CYP19A1 (0.53) | CYP19A1KMT2ACRHBPCRHR2MEN1 | |
| SCHEMBL30236490 | 0.74 | ALDH1A1 (0.44) | KMT2AMEN1MAPTKCNH2ALDH1A1 | |
| SCHEMBL30236931 | 0.74 | PDGFRB (0.41) | CYP19A1CNR2KMT2AMEN1MAPT | |
| SCHEMBL29272401 | 0.74 | PDGFRB (0.41) | CYP19A1CNR2KMT2AMEN1MAPT | |
| SCHEMBL3162128 | 0.74 | KCNH2 (0.63) | KMT2ACRHBPCRHR2MEN1MAPT | |
| SCHEMBL346269 | 0.73 | KMT2A (0.67) | CYP19A1CNR2KMT2ACRHBPCRHR2 | |
| SCHEMBL6769652 | 0.73 | ALDH1A1 (0.42) | KMT2AMEN1MAPTALDH1A1LMNA | |
| SCHEMBL8362958 | 0.73 | LMNA (0.68) | CYP19A1KMT2AMEN1MAPTKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104910148-B | Aminotriazole(ATA) and pyridine and its as kinase inhibitor purposes | 西格诺药品有限公司 | 2017-06-27 | — | — | CN | disclosed |
| EP-2344494-B1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| CN-104910148-A | Aminotriazolopyridines and use thereof as kinase inhibitors | SIGNAL PHARM LLC | 2015-09-16 | — | — | CN | disclosed |
| CN-102203093-B | Aminotriazolopyridines and their use as kinase inhibitors | SIGNAL PHARM LLC | 2015-05-13 | — | — | CN | disclosed |
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | disclosed |
| US-8299056-B2 | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-30 | — | — | US | disclosed |
| CN-102203093-A | Aminotriazolopyridines and their use as kinase inhibitors | SIGNAL PHARM LLC | 2011-09-28 | — | — | CN | disclosed |
| EP-2344494-A1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
| WO-2010027500-A1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | CYP19A1 1026/4885CNR2 745/4885SLC2A1 3557/4885 |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | CYP19A1 1026/4885CNR2 745/4885SLC2A1 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.